Rights issue 2026

Dicot Pharma’s phase 2b study is planned to be conducted in the U.S. and Europe, with a start date in the second half of 2026. To finance the study, the Board has determined that a preferential issued is preferable from a shareholder perspective and to further increase value ahead of anticipated out-licensing and partnerships.
The subscription price is set at SEK 1.36 per unit, corresponding to SEK 0.17 per share. For every 13 shares held as of May 19, the shareholder has received 13 unit rights. For every 13 unit rights, the holder may subscribe for one unit at SEK 1.36 from May 21 through June 4, 2026. This unit consists of 8 new shares and 2 warrants in series TO 7. The warrants are issued free of charge.
Unit rights that are not exercised expire worthless. If you own unit rights that you do not intend to exercise, you can sell them; similarly, anyone wishing to subscribe for more than their own unit rights can purchase additional ones. Trading in unit rights takes place from May 21 through June 1, 2026.
You subscribe for units and trade in unit rights through your broker, such as Avanza or Nordnet, or through your bank. Please note that your broker/bank may close subscriptions/trading earlier than the dates listed above.
If the offering is fully subscribed, Dicot Pharma will receive SEK 210 million before transaction costs, which are estimated at SEK 29 million if all guarantors receive cash compensation. The guarantors have the option to receive their compensation in the form of units.
The offering is 80% secured, corresponding to SEK 168 million, by existing and new strategic investors. This means that the phase 2b study is fully funded.
If the offering is oversubscribed, the Board may decide to expand the offering through a directed issue corresponding to a maximum of SEK 21 million.
The Series TO 7 warrants entitle the holder to subscribe for one new share next year during the period May 10–24, 2027, at a price corresponding to 70 percent of the average price of the Company’s share from April 20 to May 4, 2027. However, the exercise price will be no less than SEK 0.17 and no more than SEK 0.25 per share. The Company may receive a maximum of SEK 79 million before costs upon full exercise of the warrants.